focus -WSS

focus

author：comprehensive 2025-10-01 04:10:24 - browse：9

Sen. Rand Paul (C) (R-KY) questions Homeland Security Secretary Alejandro Mayorkas and FBI Director Christopher Wray during a hearing held by the Senate Homeland Security and Governmental Affairs Committee October 31, 2023 in Washington, DC. — Sen. Rand Paul (R-Ky.) Win McNamee/Getty Images

WASHINGTON — A Senate panel Wednesday passed a bill aimed at preventing certain Chinese companies from doing business in the United States. The sole no vote was by Sen. Rand Paul (R-Ky.), who worries that Congress is using anger toward China as a cover for advancing parochial interests.

Many in Congress are worried the Chinese government and military are using the rising dominance of national companies to gather Americans’ genetic information, which could be used for reasons that range from creating bioweapons to giving China a leg up in drug development.

The Biosecure Act, by Homeland Security and Governmental Affairs Chair Gary Peters (D-Mich.), is a response to those concerns. The bill would block the U.S. government from contracting with companies that do business with Chinese “biotechnology companies of concern,” and it names four companies that must be on that list: BGI Genomics, MGI, Complete Genomics, WuXi AppTec, and any subsidiary, parent affiliate, or successor of these companies.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Hospitals warn Medicare's drug payment fix is ‘unlawful’

WSS

AdventHealth escalates lawsuit against insurance vendor Multiplan

New weight loss drugs work. But how can they best be used?

White House finalizes ITC's import ban of latest Apple Watches

FDA has safety concerns on CRISPR

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

UCB departs biotech trade group BIO

entertainment

focus

focus

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Readout Newsletter: XBI biotech index, Akero Therapeutics

Medicare details structure of new drug price negotiation program

Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

Hepatitis C has a cure — but many Americans still lack access to it

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

Peter Hotez and the public health issue of online harassment

3 medical device trends to watch in 2024

Medical leaders decry Supreme Court decision on affirmative action

Maker of FluMist seeks to allow at

knowledge

Feng Zhang, Grail founder join forces on new gene editing startup

UCB departs biotech trade group BIO

White House finalizes ITC's import ban of latest Apple Watches

JPM 2024 Day 3: Biotech Updates from Verve, Roivant, etc

Why Sanofi got shellacked over its spinoff

First Opinion Podcast: How to protect health care in times of war

explore

hotspot

leisure time

hotspot